Multiple sclerosis (MS) is an inflammatory demyelinating dis-ease with unknown origin. Several studies suggest lower levels of serum uric acid (UA), an endogenous antioxidant, in MS patients. Methods: In this study, we aimed to investigate serum UA levels in relapsing-remitting (RR) MS. In addition we compared serum UA levels by means of clinical activity, expanded disability status scale (EDSS) and disease duration.
Results: In the present study, mean serum UA levels were lower in RRMS and relapse patients with MS than in the other neuro-logical diseases (OND) group, but the difference did not reach significance level. UA levels did not correlate with clinical activity, EDSS score and disease duration either in relapse or remitting or both of them.
Conclusion: In conclusion, this study suggests serum uric acid lev-els may affect neither pathogenesis of MS nor activity of disease. Further studies are needed to clarify the role of uric acid in MS patients.